Platinum Investment Management Ltd. Sells 875,470 Shares of Merck & Co., Inc. $MRK

Platinum Investment Management Ltd. trimmed its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 93.3% during the fourth quarter, HoldingsChannel reports. The firm owned 63,316 shares of the company’s stock after selling 875,470 shares during the quarter. Merck & Co., Inc. accounts for about 1.5% of Platinum Investment Management Ltd.’s investment portfolio, making the stock its 13th biggest holding. Platinum Investment Management Ltd.’s holdings in Merck & Co., Inc. were worth $6,665,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Kingdom Financial Group LLC. bought a new stake in shares of Merck & Co., Inc. during the 4th quarter worth $25,000. IFC & Insurance Marketing Inc. purchased a new stake in Merck & Co., Inc. in the 4th quarter worth about $31,000. High Note Wealth LLC increased its holdings in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after acquiring an additional 109 shares during the last quarter. Gilpin Wealth Management LLC purchased a new stake in Merck & Co., Inc. in the 4th quarter worth about $32,000. Finally, Tucker Asset Management LLC purchased a new stake in Merck & Co., Inc. in the 4th quarter worth about $34,000. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Stock Down 1.4%

MRK stock opened at $119.05 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The firm has a market capitalization of $294.04 billion, a PE ratio of 33.54, a PEG ratio of 2.72 and a beta of 0.21. Merck & Co., Inc. has a twelve month low of $76.66 and a twelve month high of $125.14. The stock has a 50-day simple moving average of $116.55 and a two-hundred day simple moving average of $113.23.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities analysts predict that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th will be issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Monday, June 15th. Merck & Co., Inc.’s payout ratio is presently 95.77%.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a report on Monday, March 30th. Barclays assumed coverage on Merck & Co., Inc. in a report on Friday, February 20th. They issued an “overweight” rating and a $140.00 price objective for the company. JPMorgan Chase & Co. lifted their price objective on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a report on Monday, April 6th. Wells Fargo & Company decreased their price objective on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Finally, Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average price target of $128.18.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck Animal Health announced a definitive agreement to acquire TARGAN, a poultry biodevice company, which could strengthen Merck’s animal health division and broaden its technology-driven growth opportunities. Merck Animal Health to Acquire TARGAN
• Positive Sentiment: Merck saw unusually heavy call option buying, with traders purchasing 170,441 calls, a sharp jump versus normal volume that often signals bullish expectations from sophisticated investors.
• Positive Sentiment: Wells Fargo reiterated a buy rating on Merck, while another article highlighted that Wall Street’s overall bullish view continues to keep MRK on investors’ radar.
• Neutral Sentiment: Merck has also been featured in broader market commentary and “most searched” lists, suggesting rising attention rather than a new fundamental catalyst.
• Neutral Sentiment: One article noted Merck’s recent trading uptick but said it lagged the broader market, indicating modest price strength rather than a major breakout. Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.